1
|
Martinez Perez D, Garcia B, Roa D, Gay H, Chetty I, Hermansen M, Mcleod M, Hao J, Castaneda S, Lo C, Sherry A, Del Castillo Pacora R, Sarria Bardales G, Li B. PO-1284: Evaluation of the Effectiveness of Telehealth Courses for SBRT/SRS Training in Latin America. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01302-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
2
|
Arevalo-Saenz A, Gonzalez-Alvaro I, Pulido-Rivas P, Vicente E, Garcia E, Castaneda S, Ocon E, Gomez-Leon N, Sola RG. [Medullar thoracic compression by tophaceous gout: presentation of a case and review of the literature]. Rev Neurol 2017; 65:368-372. [PMID: 28990647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
INTRODUCTION Spine involvement in gout is an extremely uncommon complication. Dorsalgia and quadriplegia are some manifestations that may occur, although these symptoms are seen more frequently in other more prevalent pathologies, such as spinal tumors. CASE REPORT We present an unusual case of thoracic spinal cord compression at T10-T11 level caused by the extradural deposit of tophaceous material in a 52-year-old woman with uncontrolled chronic tophaceous gout. In addition to intensive medical treatment, the patient required surgery (hemilaminectomy and spinal decompression) and subsequent rehabilitation. Overall and neurological evolution were satisfactory.
Collapse
Affiliation(s)
| | | | - P Pulido-Rivas
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - E Vicente
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - E Garcia
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - S Castaneda
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - E Ocon
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - N Gomez-Leon
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| | - R G Sola
- Hospital Universitario de la Princesa, 28006 Madrid, Espana
| |
Collapse
|
3
|
Cavagna L, Govoni M, Lopez Longo F, Airò P, Neri R, Sifuentes Giraldo W, Iannone F, Nuno L, Montecucco C, Caporali R, Furini F, Foschi V, Franceschini F, Cavazzana I, Quartuccio L, Bartoloni Bocci E, Giannini M, Sciré C, Fusaro E, Parisi S, Paolazzi G, Barausse G, Selmi C, Bachiller Corral J, Bravi E, Bajocchi G, Pellerito R, Russo A, Barsotti S, Pina Murcia T, Castaneda S, Ortego-Centeno N, Schwarting A, Specker C, Saketkoo L, Weinmann-Menke J, Triantafyllias K, Gonzalez-Gay MA. FRI0477 Isolated Arthritis Revealing an Underlying Anti-Synthetase Syndrome: Results from a Multicentre International Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Abstract
Report three cases of painful legs and moving toes (PLMT) syndrome responsive to pregabalin along with a review of its literature. Three patients with PLMT syndrome improved with pregabalin. The first and third patient reported improvement in pain scores, quality of life, and quality of sleep sustained over time. The second and third patient had near complete remission of toe movements, but pregabalin was discontinued in the second patient due to aggravation of leg edema. PLMT is a rare and debilitating disorder characterized by lower limb pain and involuntary toes or feet movements. Its pathophysiology remains unknown and its therapy refractory to most drugs, except for pregabalin, as shown in this case series. PLMT is a rare and incapacitating syndrome due to the lack of an effective pain therapy. We report three patients with PLMT who favorable responded to pregabalin. We propose pregabalin be considered in the management of PLMT.
Collapse
Affiliation(s)
- F H Rossi
- Department of Neurology, Orlando Veteran Affairs Medical Center in Orlando, Orlando, Fl, United States of America
| | | | | | | | | | | |
Collapse
|
5
|
Herrero-Beaumont G, Roman-Blas JA, Largo R, Berenbaum F, Castaneda S. Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. Ann Rheum Dis 2011; 70:1523-5. [DOI: 10.1136/ard.2011.151233] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
6
|
Zhang Y, Castaneda S, Kim S, Qu Z, Kraft P, Wang M, Dumble M, Zhao H, Greenberger L, Horak I. 218 Down-modulation of the androgen receptor (AR) with EZN-4176 inhibits the growth of prostate tumor and potentiates the inhibitory effect of MDV-3100, a novel anti-androgen. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71923-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
7
|
Radyushkin K, El-Kordi A, Boretius S, Castaneda S, Ronnenberg A, Reim K, Bickeböller H, Frahm J, Brose N, Ehrenreich H. Complexin2 null mutation requires a 'second hit' for induction of phenotypic changes relevant to schizophrenia. Genes Brain Behav 2010; 9:592-602. [PMID: 20412316 DOI: 10.1111/j.1601-183x.2010.00590.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Schizophrenia is a devastating disease that affects approximately 1% of the population across cultures. Its neurobiological underpinnings are still unknown. Accordingly, animal models of schizophrenia often lack construct validity. As concordance rate in monozygotic twins amounts to only 50%, environmental risk factors (e.g. neurotrauma, drug abuse, psychotrauma) likely act as necessary 'second hit' to trigger/drive the disease process in a genetically predisposed individual. Valid animal models would have to consider this genetic-environmental interaction. Based on this concept, we designed an experimental approach for modeling a schizophrenia-like phenotype in mice. As dysfunction in synaptic transmission plays a key role in schizophrenia, and complexin2 (CPLX2) gene expression is reduced in hippocampus of schizophrenic patients, we developed a mouse model with Cplx2 null mutation as genetic risk factor and a mild parietal neurotrauma, applied during puberty, as environmental 'second hit'. Several months after lesion, Cplx2 null mutants showed reduced pre-pulse inhibition, deficit of spatial learning and loss of inhibition after MK-801 challenge. These abnormalities were largely absent in lesioned wild-type mice and non-lesioned Cplx2 null mutants. Forced alternation in T-maze, object recognition, social interaction and elevated plus maze tests were unaltered in all groups. The previously reported mild motor phenotype of Cplx2 null mutants was accentuated upon lesion. MRI volumetrical analysis showed a decrease of hippocampal volume exclusively in lesioned Cplx2 null mutants. These findings provide suggestive evidence for the 'second hit' hypothesis of schizophrenia and may offer new tools for the development of advanced treatment strategies.
Collapse
Affiliation(s)
- K Radyushkin
- Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Liao B, Qu T, Kosek J, Castaneda S, Sapra P, Zhang Y, Bandaru R, Greenberger L, Horak I. 312 POSTER EZN-3920, an ErbB3-locked nucleic acid-based RNA inhibitor, potently silences target gene expression in tumor cells grown in vitro and in vivo. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72246-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
9
|
Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol 2005; 56:455-64. [PMID: 15947929 DOI: 10.1007/s00280-005-1022-3] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2004] [Accepted: 01/06/2005] [Indexed: 10/25/2022]
Abstract
PURPOSE The epidermal growth factor receptor (EGFR), a protein tyrosine kinase expressed in many types of human cancers including colon and breast, has been strongly associated with tumor progression. Cetuximab, an IgG1 anti-EGFR chimeric mouse/human monoclonal antibody, has been proven to be effective in the treatment of advanced colon cancer. To date, there has not been a study to systematically evaluate the pharmacokinetics (PK) of Cetuximab in a preclinical model and to further explore any correlation of drug exposure between animal models and cancer patients. In the present study, we characterized the PK of Cetuximab in nude mice at efficacious dose levels and further compared the preclinical optimal dose and active plasma drug concentration with those determined in clinical studies. EXPERIMENTAL DESIGN The antitumor activity of Cetuximab was evaluated using the GEO human colon carcinoma xenografts implanted subcutaneously in nude mice. The drug was administered ip every 3 days for five total injections (inj) (q3dx5) at dose levels ranging from 1 mg/inj to 0.04 mg/inj. The plasma PK of Cetuximab was determined at dose levels of 1.0, 0.25, and 0.04 mg/inj with a single bolus iv or ip administration in nude mice. The tumoral PK of Cetuximab was determined at dose levels of 0.25, and 0.04 mg/inj with a single bolus ip administration in nude mice bearing GEO tumor xenografts. The plasma and tumoral levels of Cetuximab were quantitated by an ELISA assay. RESULTS Cetuximab demonstrated a dose-dependent antitumor activity at dose levels of 0.25, 0.1, and 0.04 mg/inj, with a statistically significant tumor growth delay (in reaching a tumor target size of 1 gm) of 18 days (P < 0.001), 12.3 days (P < 0.01), and 10 days (P < 0.01) for 0.25, 0.1, and 0.04 mg/inj, respectively. A separate study employing the same treatment schedule showed that Cetuximab was equally active at dose levels ranging from 0.25 mg/inj to 1 mg/inj. Therefore, dose levels of Cetuximab from 1 mg/inj to 0.04 mg/inj can be considered to be within the efficacious range, while dose levels of 0.25 mg/inj or higher appeared to be optimal for the antitumor activity of Cetuximab in the GEO tumor model. When Cetuximab was given iv to mice, the elimination half life (t(1/2)) was 39.6, 37.8, and 42.2 h for doses of 1.0, 0.25, and 0.04 mg/inj, respectively, suggesting a similar disposition kinetics of Cetuximab within this dose range. The volume of distribution (V(d)) ranged from 0.062 l/kg to 0.070 l/kg, suggesting that Cetuximab is primarily confined to the plasma compartment with limited peripheral tissue distribution. Clearance (CL) was similar and no apparent PK saturation was observed across the dose ranging from 0.04 mg/inj to 1.0 mg/inj. When mice were administered with a single bolus ip administration at doses of 1, 0.25, and 0.04 mg/inj, the maximum plasma concentration (C(max)) was 407.6, 66.4, and 16.5 microg/ml. The area under the curve of plasma drug concentration (AUC) was 19212.4, 3182.4, and 534.5 microg/ml h, for 1.0, 0.25, and 0.04 mg/inj, respectively. The average steady state plasma concentration (C(ss avg)) for the multiple dosing schedule was estimated to be 73.1 microg/ml at 0.25 mg/inj and was considered as an active plasma drug concentration. The maximum tumoral concentration of Cetuximab was 2.6 and 0.53 ng/mg-tumor while the tumoral drug exposure was 112.6 and 18.3 ng/mg h for 0.25 and 0.04 mg/inj, respectively. The EGFR was estimated to be nearly completely occupied by Cetuximab at the optimal dose of 0.25 mg/inj. CONCLUSION In the present study, we compared the preclinical optimal dose and the corresponding active plasma concentration determined in mice with those being observed in cancer patients, i.e. 65-100 microg/ml. The preclinical optimal dose of 0.25 mg/inj was significantly lower than the current clinical dose. However, the active plasma concentration at 0.25 mg/inj is within the range of the active drug concentrations in cancer patients treated with Cetuximab under the current optimal dosing regimen. It appears that the active plasma drug concentration determined in preclinical model predicts better than the optimal preclinical dose for the clinical development of antibody drugs.
Collapse
Affiliation(s)
- F R Luo
- Pharmaceutical Research Institute, Oncology Drug Discovery, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Lee FY, Castaneda S, Inigo I, Kan D, Paul B, Wen ML, Fairchild C, Clark E, Lee H. Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.561] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Y. Lee
- Bristol-Myers Squibb Co, Princeton, NJ
| | | | - I. Inigo
- Bristol-Myers Squibb Co, Princeton, NJ
| | - D. Kan
- Bristol-Myers Squibb Co, Princeton, NJ
| | - B. Paul
- Bristol-Myers Squibb Co, Princeton, NJ
| | - M.-L. Wen
- Bristol-Myers Squibb Co, Princeton, NJ
| | | | - E. Clark
- Bristol-Myers Squibb Co, Princeton, NJ
| | - H. Lee
- Bristol-Myers Squibb Co, Princeton, NJ
| |
Collapse
|
11
|
Abstract
OBJECTIVES To review the cases receiving peripartum hysterectomies treated in this hospital during the period 1967-1995. Clinical characteristics, indications, and results were more closely analyzed. STUDY DESIGN A chart review of all cases operated since January 1967 to December 1995 was done. Demographic and clinical data were extracted, coded, and entered into a computer file for analysis. Indications, type of operation, pre-op planning or emergency decision, blood loss, transfusion, complications, were compared and cross-tabulated. Statistical analysis included: chi-square and Fisher exact tests, where appropriate, and two-sample t test. RESULTS In 58% of 217 cases the operation was planned, and total hysterectomy was done in 94%. Indications changed through the years, from predominantly elective to almost exclusively emergencies. These were mostly bleeding complications, in particular placenta previa and/or accreta. The presence of a uterine scar or submucous fibroid was associated with 79% (26/33) of accretas, and 51% (19/37) of previas. Among the 126 planned, 57% did not receive a transfusion and 84% of 91 emergencies did have one. The average amount of blood received by the latter was 3009 ml compared to 1262 ml for the former (p < 0.0001). There was a direct relationship between amount of blood loss and volume transfused. There were 26% intraoperatory bleeding complications and 5% urinary tract injuries. Postoperatory morbidity such as bleeding, infections, wound dehiscence, and others was observed in 17% of planned, and 23% of emergencies. Twelve patients needed another operation to treat some of these complications. There were no deaths recorded. CONCLUSIONS Peripartum hysterectomy is a major operation, and in current times almost always an emergency with high risk for significant blood loss. The obstetrician should be ready to do it, and an early decision should save blood and prevent complications. Postoperative complications, mostly bleeding and infections may be severe. Early intervention and proper technique facilitate good outcomes.
Collapse
Affiliation(s)
- S Castaneda
- Departments of Obstetrics and Gynecology, and Health Studies, University of Chicago, Chicago, Illinois, USA
| | | | | |
Collapse
|
12
|
Herrero-Beaumont G, Castaneda S, Fernandez-Vallado P. Exacerbation of B27 positive spondyloarthropathy by enteric infections. J Rheumatol 1985; 12:389. [PMID: 3875723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|